Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Net Cash Flow (2018 - 2025)

TELA Bio has reported Net Cash Flow over the past 8 years, most recently at $21.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $21.2 million for Q4 2025, down 39.84% from a year ago — trailing twelve months through Dec 2025 was -$1.6 million (down 127.45% YoY), and the annual figure for FY2025 was -$1.6 million, down 127.45%.
  • Net Cash Flow for Q4 2025 was $21.2 million at TELA Bio, up from -$5.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TELA hit a ceiling of $35.2 million in Q4 2024 and a floor of -$12.2 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was -$8.1 million (2021), compared with a mean of -$1.2 million.
  • Biggest five-year swings in Net Cash Flow: soared 767.96% in 2023 and later crashed 130.4% in 2024.
  • TELA Bio's Net Cash Flow stood at -$9.7 million in 2021, then decreased by 26.23% to -$12.2 million in 2022, then grew by 8.38% to -$11.2 million in 2023, then surged by 413.55% to $35.2 million in 2024, then crashed by 39.84% to $21.2 million in 2025.
  • The last three reported values for Net Cash Flow were $21.2 million (Q4 2025), -$5.4 million (Q3 2025), and -$7.7 million (Q2 2025) per Business Quant data.